Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation
Main finding · Incident epilepsyResult — go to the resultHazard ratio 0.77 95% CI 0.64–0.93Authors' conclusion
Our results indicated that use of TZDs was associated with reduced risk of epilepsy in the study population. More studies are needed to confirm and replicate the study results in other settings and populations..
Study context
- Population
- Chinese patients with T2D aged 18–100 years, new users of TZDs or alpha glucosidase inhibitors (AGIs); mean age 60.3 (SD 12.8) years, 47.2% female
- Participants
- 22,128 vs 79,166
- Exposure
- TZD vs alpha glucosidase inhibitors in T2D
- TZDsn = 22,128
- AGIsn = 79,166reference
- Outcome
- Incident epilepsy identified by ICD-10 codes
Methodological detailsactive-comparator new-user (ACNU) design, inverse probability of treatment weighting
- Active-comparator new-user (ACNU) design
- Inverse probability of treatment weighting
Main finding
Incident epilepsy
Hazard ratio
0.77
95% CI 0.64–0.93
By group
TZDs
140.1 per 100,000 person-years
AGIs
208.2 per 100,000 person-years
TZDsvs AGIs
HR 0.77 (95% CI 0.64–0.93)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Association consistent in various subgroup and sensitivity analyses
Original publication
Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation. Diabetes Res Clin Pract. Published 23 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →